Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Read how Candel is advancing cancer immunotherapies through our viral delivery platform in this @DDWJournal interview with our CEO @paulpetertak.
Our approach teaches immune cells to recognize and attack cancer cells directly in tumors.
$CADL
During #MensHealthWeek, we reflect on our commitment to developing treatments for prostate, lung, & pancreatic cancer. Our experimental medicines show promising results with potential to transform treatment paradigms & offer hope for patients with difficult-to-treat solid tumors.
Very funny. Sadly, all too true. Can be overcome with perseverance and a relentless focus on doing the right.
🧪 The Most Miserable Place on Earth: Biotech
Preclinical?
🗣️ “It’s just an idea.”
Phase 1?
🗣️ “Sell the dream.”
Phase 2?
🗣️“Sample’s too small. Biomarkers don’t count. Comparator’s weak. etc etc ”
Phase 3?
🗣️ “It’ll never be a product. Market’s too crowded..”
FDA approval?…
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) ☢️for newly diagnosed localized #ProstateCancer presented at #ASCO25
https://meetings.asco.org/abstracts-presentations/243847
In a pivotal phase 3 trial, the addition…
